Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients

Pharmaceutical Research

Volumn 26, Issue 8, 2009, Pages 1952-1962

  Ramon Lopez, Amelia ^a   Nalda Molina, Ricardo ^a   Valenzuela, Belen ^a   Perez Ruixo, Juan Jose ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b NONE   (Spain)

Author keywords

Cancer; High dose chemotherapy; Neutropenia; Peripheral blood stem cell transplantation; Population pharmacokinetics pharmacodynamics; RHuG CSF

Indexed keywords

ACICLOVIR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUCONAZOLE; MESNA; NORFLOXACIN; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; TROPISETRON;

ACCURACY; ADULT; ARTICLE; BOOTSTRAPPING; BREAST CANCER; CANCER PATIENT; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SENSITIVITY; FEEDBACK SYSTEM; HIGH RISK PATIENT; HUMAN; MITOSIS RATE; NEUTROPENIA; NEUTROPHIL COUNT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTION; PRIORITY JOURNAL; STEM CELL; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPENIA;

EID: 67650067179     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9910-6     Document Type: Article

References (58)

1. K Antman L Ayash A Elias C Wheeler M Hunt JP Eder 1992 A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 10 102 10
2. JO Armitage 1994 Bone marrow transplantation N Engl J Med 330 827 38 10.1056/NEJM199403243301206
3. M Attal JL Harousseau AM Stoppa JJ Sotto JG Fuzibet JF Rossi 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 91 7 10.1056/NEJM199607113350204
4. M Attal F Huguet D Schlaifer C Payen M Laroche B Fournie 1992 Intensive combined therapy for previously untreated aggressive myeloma Blood 79 1130 6
5. Beal SL, Sheiner LB. NONMEM users guides. Hanover (MD): GloboMax, LLC.; 1992.
6. J Beyer N Schwella J Zingsem I Strohscheer I Schwaner H Oettle 1995 Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison J Clin Oncol 13 1328 35
7. DC Dale WC Liles C Llewellyn TH Price 1998 Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers Am J Hematol 57 7 15 10.1002/(SICI) 1096-8652(199801) 57:1<7::AID-AJH2>3.0.CO;2-0 (Pubitemid 28047192)
8. ME de Jonge AD Huitema S Rodenhuis JH Beijnen 2004 Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction J Pharmacokinet Pharmacodyn 31 135 56 10.1023/B:JOPA. 0000034405.03895.c2
9. A Dekker S Bulley J Beyene LL Dupuis JJ Doyle L Sung 2006 Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation J Clin Oncol 24 5207 15 10.1200/JCO.2006.06.1663
10. RO Dillman NM Barth SK Nayak C DeLeon A O'Connor L Morrelli 1996 High-dose chemotherapy with autologous stem cell rescue in breast cancer Breast Cancer Res Treat 37 277 89 10.1007/BF01806509
11. AD Elias L Ayash KC Anderson M Hunt C Wheeler G Schwartz 1992 Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer Blood 79 3036 44
12. EI Ette 1997 Stability and performance of a population pharmacokinetic model J Clin Pharmacol 37 486 95
13. AJ Ferreri R Crocchiolo A Assanelli S Govi M Reni 2008 High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions Leuk Lymphoma 49 2042 7 10.1080/10428190802381238
14. LE Friberg A Henningsson H Maas L Nguyen MO Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 4713 21 10.1200/JCO.2002.02.140
15. J Gabrielsson WJ Jusko L Alari 2000 Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles Biopharm Drug Dispos 21 41 52 10.1002/1099-081X(200003) 21:2<41::AID-BDD217>3.0.CO;2-D (Pubitemid 30839700)
16. P Gill M Litzow J Buckner C Arndt T Moynihan T Christianson 2008 High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system Cancer 112 1805 11 10.1002/cncr.23362
17. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. 2008. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev. CD004024
18. AM Gianni S Siena M Bregni C Tarella AC Stern A Pileri 1989 Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation Lancet 2 580 5 10.1016/S0140-6736(89) 90711-3
19. A Grigg CG Begley CA Juttner J Szer LB To D Maher 1993 Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy Bone Marrow Transplant 11 Suppl 2 23 9
20. BE Hillner TJ Smith CE Desch 1994 Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments Pharmacoeconomics 6 114 26 10.2165/00019053-199406020-00004
21. J Hing JJ Perez-Ruixo K Stuyckens A Soto-Matos L Lopez-Lazaro P Zannikos 2008 Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis®) induced neutropenia Clin Pharmacol Ther 83 130 43 10.1038/sj.clpt.6100259
22. P Jacqmin E Snoeck EA van Schaick R Gieschke P Pillai JL Steimer 2007 Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model J Pharmacokinet Pharmacodyn 34 57 85 10.1007/s10928-006-9035-z
23. M Joerger AD Huitema DJ Richel C Dittrich N Pavlidis E Briasoulis 2007 Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug de Clin Cancer Res 13 6410 8 10.1158/1078-0432.CCR-07-0064
24. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther 82 17 20 10.1038/sj.clpt.6100241
25. MO Karlsson T Anehall LE Friberg A Henningsson C Kloft M Sandström 2005 Pharmacokinetic/pharmacodynamic modelling in oncological drug development Basic Clin Pharmacol Toxicol 96 206 11 10.1111/j.1742-7843.2005.pto960310.x
26. SJ Kathman DH Williams JP Hodge M Dar 2007 A Bayesian population PK-PD model of ispinesib-induced myelosuppression Clin Pharmacol Ther 81 88 94 10.1038/sj.clpt.6100021
27. C Kloft J Wallin A Henningsson E Chatelut MO Karlsson 2006 Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs Clin Cancer Res 12 5481 90 10.1158/1078-0432.CCR-06-0815
28. JE Latz MO Karlsson JJ Rusthoven A Ghosh RD Johnson 2005 A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy Cancer Chemother Pharmacol 57 412 26 10.1007/s00280-005-0077-5
29. JE Latz JJ Rusthoven MO Karlsson A Ghosh RD Johnson 2005 Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy Cancer Chemother Pharmacol 57 427 35 10.1007/s00280-005-0035-2
30. F Leger WJ Loos R Bugat RH Mathijssen M Goffinet J Verweij 2004 Mechanism-based models for topotecan-induced neutropenia Clin Pharmacol Ther 76 567 78 10.1016/j.clpt.2004.08.008
31. JW Mandema D Verotta LB Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J Pharmacokinet Biopharm 20 511 28 10.1007/BF01061469
32. H Minami Y Sasaki N Saijo T Ohtsu H Fujii T Igarashi 1998 Indirect-response model for the time course of leukopenia with anticancer drugs Clin Pharmacol Ther 64 511 21 10.1016/S0009-9236(98) 90134-5
33. H Mukae D Zamfir D English JC Hogg SF van Eeden 2000 Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor: intravascular behavior Hematol J 1 159 71 10.1038/sj.thj.6200023
34. T Muramatsu T Shinozuka T Hirasawa H Tsukada H Maeda T Miyamoto 2006 Treatment strategy for recurrent and refractory epithelial ovarian cancer: efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation Acta Histochem Cytochem 39 61 7 10.1267/ahc.05030
35. UA Nitz S Mohrmann J Fischer W Lindemann WE Berdel C Jackisch 2005 Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial Lancet 366 1935 44 10.1016/S0140-6736(05) 67784-7
36. JC Panetta P Schaiquevich VM Santana CF Stewart 2008 Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma Clin Cancer Res 14 318 25 10.1158/1078-0432.CCR-07-1243
37. P Pedrazzoli G Rosti S Secondino O Carminati T Demirer 2007 High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults Semin Hematol 44 286 95 10.1053/j.seminhematol.2007.08.009
38. WP Peters M Ross JJ Vredenburgh B Meisenberg LB Marks E Winer 1993 High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J Clin Oncol 11 1132 43
39. WP Peters GL Rosner JJ Vredenburgh EJ Shpall M Crump PG Richardson 2005 Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13 J Clin Oncol 23 10 2191 200 10.1200/JCO.2005.10. 202
40. G Pillai R Gieschke T Goggin P Jacqmin RC Schimmer JL Steimer 2004 A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis Br J Clin Pharmacol 58 618 31 10.1111/j.1365-2125.2004.02224.x
41. TH Price GS Chatta DC Dale 1996 Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans Blood 88 335 40
42. R Romberg E Olofsen E Sarton L Teppema A Dahan 2003 Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers Anesthesiology 99 788 98 10.1097/00000542- 200310000-00008
43. F Rombout L Aarons M Karlsson A Man F Mentré P Nygren 2004 Modelling and simulation in the development and use of anti-cancer agents: an underused tool? J Pharmacokinet Pharmacodyn 31 419 40 10.1007/s10928-005-5910-2
44. LK Roskos P Lum P Lockbaum G Schwab BB Yang 2006 Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects J Clin Pharmacol 46 747 57 10.1177/0091270006288731
45. M Sandstrom H Lindman P Nygren M Johansson J Bergh MO Karlsson 2006 Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients Cancer Chemother Pharmacol 58 143 56 10.1007/s00280-005-0140-2
46. M Sandstrom H Lindman P Nygren E Lidbrink J Bergh MO Karlsson 2005 Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients J Clin Oncol 23 413 21 10.1200/JCO.2005.09.161
47. C Schmoor W Sauerbrei G Bastert H Bojar M Schumacher German Breast Cancer Study Group 2001 Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF Eur J Cancer 37 1123 31
48. KA Schulman R Birch B Zhen N Pania CH Weaver 1999 Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support J Clin Oncol 17 1227 33
49. L Schwartzberg R Birch R Blanco F Wittlin J Muscato K Tauer 1993 Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy Bone Marrow Transplant 11 369 74
50. LB Sheiner DR Stanski S Vozeh RD Miller J Ham 1979 Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin Pharmacol Ther 25 358 71
51. EJ Shpall R Champlin JA Glaspy 1998 Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery Biol Blood Marrow Transplant 4 84 92 10.1053/bbmt.1998.v4.pm9763111 (Pubitemid 128540944)
52. EA Stadtmauer A O'Neill LJ Goldstein PA Crilley KF Mangan JN Ingle 2000 Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group N Engl J Med 342 1069 76 10.1056/NEJM200004133421501
53. D Testart-Paillet P Girard B You G Freyer C Pobel B Tranchand 2007 Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice Crit Rev Oncol Hematol 63 1 11 10.1016/j.critrevonc.2007.01. 005
54. LB To PG Dyson AL Branford JA Russell DN Haylock JQ Ho 1987 Peripheral blood stem cells collected in very early remission produce rapid and sustained autologous haemopoietic reconstitution in acute non-lymphoblastic leukaemia Bone Marrow Transplant 2 103 8
55. IF Troconiz MJ Garrido C Segura JM Cendrós P Principe C Peraire 2006 Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours Cancer Chemother Pharmacol 57 727 35 10.1007/s00280-005-0112-6
56. TR Ulich J del Castillo L Souza 1988 Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia Am J Pathol 133 630 8
57. KC Van Kesteren AS Zandvliet MO Karlsson RA Mathôt CJ Punt JP Armand 2005 Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam Invest New Drugs 23 225 34 10.1007/s10637-005- 6730-3
58. L Weissbach J Beyer 2007 High-dose chemotherapy and hematopoietic stem cell transplantation in patients with germ cell cancer Urologe A 46 416 9 10.1007/s00120-007-1318-5